跳至主要内容
临床试验/EUCTR2017-003423-30-NL
EUCTR2017-003423-30-NL进行中(未招募)1 期

Randomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome.Effects on social behaviour.

Dutch Growth Research Foundation0 个研究点目标入组 33 人开始时间: 2017年10月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • - Genetically confirmed diagnosis of Prader-Willi syndrome
  • - Children aged 3 to 10.99 years
  • - Informed consent
  • - Currently on growth hormone treatment for at least 1 year
  • - Behavioural characteristics such as reduced social reciprocity and interaction, repetitive behaviour or temper tantrums, and/or be in nutritional phase 2b or 3 according to Miller (increased interest in food, hyperphagia)
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 33
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • - Severe psychiatric problems
  • - Non-cooperative behaviour
  • - Allergic reactions or hypersensitivity for oxytocin
  • - Serious illness
  • - Cardiac abnormalities
  • - Extremely low dietary intake or less than required itnake acoording to WHO
  • - Medication to reduce weight (fat)

研究者

发起方
Dutch Growth Research Foundation

相似试验